T1	p 103 145	and vomiting after breast cancer surgery :
T2	p 218 270	Japanese patients . BACKGROUND Breast cancer surgery
T3	p 290 311	patient under general
T4	p 449 457	patients
T5	p 470 496	mastectomy ( with axillary
T6	p 654 682	women who undergo mastectomy
T7	p 888 902	cancer surgery
T8	p 906 925	Japanese patients .
T9	p 1011 1030	Japanese women were
T10	p 1691 1822	total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included in the study .
T11	p 1834 1863	group comprised 25 patients .
T12	p 2753 2803	Japanese women who underwent breast cancer surgery
T13	i 20 62	propofol , droperidol , and metoclopramide
T14	i 190 208	placebo-controlled
T15	i 312 322	anesthesia
T16	i 470 480	mastectomy
T17	i 488 496	axillary
T18	i 556 564	propofol
T19	i 570 581	subhypnotic
T20	i 624 631	placebo
T21	i 754 770	subhypnotic dose
T22	i 774 782	propofol
T23	i 792 846	conventional antiemetics droperidol and metoclopramide
T24	i 984 1002	placebo-controlled
T25	i 1073 1309	administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture . A standard general anesthetic technique , including sevoflurane and air in oxygen
T26	i 2070 2078	propofol
T27	i 2105 2115	droperidol
T28	i 2146 2160	metoclopramide
T29	i 2188 2195	placebo
T30	i 2296 2304	propofol
T31	i 2325 2335	droperidol
T32	i 2342 2350	propofol
T33	i 2355 2365	droperidol
T34	i 2441 2455	metoclopramide
T35	i 2643 2651	propofol
T36	i 2666 2679	droperidol 20
T37	i 2710 2720	anesthesia
T38	i 2860 2883	propofol and droperidol
T39	i 2898 2936	metoclopramide 0.2 mg/kg and placebo .
T40	o 82 115	postoperative nausea and vomiting
T41	o 393 399	nausea
T42	o 404 412	vomiting
T43	o 415 419	PONV
T44	o 1296 1299	air
T45	o 1303 1309	oxygen
T46	o 1339 1343	PONV
T47	o 1549 1574	extrapyramidal symptoms .
T48	o 1591 1600	integrity
T49	o 1942 1962	patient demographics
T50	o 1965 1999	surgery type , or awakening time .
T51	o 2004 2025	prevalences of PONV 0
T52	o 2240 2258	prevalence of PONV
T53	o 2407 2418	prevalences
T54	o 2422 2426	PONV
T55	o 2501 2524	Extrapyramidal symptoms
T56	o 2597 2601	PONV
T57	o 2825 2829	PONV